Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.7% – What’s Next?

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) dropped 4.7% on Thursday . The company traded as low as $14.76 and last traded at $14.81. Approximately 109,639 shares traded hands during trading, a decline of 95% from the average daily volume of 2,353,063 shares. The stock had previously closed at $15.54.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on DYN shares. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Piper Sandler restated an “overweight” rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a report on Monday, September 23rd. Chardan Capital reaffirmed a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Friday, January 10th. Robert W. Baird started coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 target price for the company. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Dyne Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $49.91.

Dyne Therapeutics Price Performance

The stock’s 50-day moving average price is $25.63 and its 200 day moving average price is $33.33. The firm has a market cap of $1.44 billion, a P/E ratio of -3.97 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, analysts forecast that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Oxana Beskrovnaya sold 2,334 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $65,632.08. Following the completion of the sale, the insider now owns 201,685 shares in the company, valued at approximately $5,671,382.20. This trade represents a 1.14 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jason P. Rhodes sold 782 shares of the stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $33.10, for a total transaction of $25,884.20. Following the completion of the transaction, the director now directly owns 15,962 shares in the company, valued at approximately $528,342.20. This represents a 4.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,071 shares of company stock worth $606,476. Company insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Large investors have recently added to or reduced their stakes in the stock. FMR LLC grew its holdings in shares of Dyne Therapeutics by 69.7% during the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after purchasing an additional 3,707,734 shares in the last quarter. Janus Henderson Group PLC grew its stake in Dyne Therapeutics by 47.3% during the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock worth $244,755,000 after buying an additional 2,189,339 shares in the last quarter. State Street Corp increased its holdings in Dyne Therapeutics by 13.8% in the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after buying an additional 440,890 shares during the period. RTW Investments LP raised its position in shares of Dyne Therapeutics by 6.8% in the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock valued at $244,926,000 after buying an additional 431,503 shares in the last quarter. Finally, RA Capital Management L.P. raised its position in shares of Dyne Therapeutics by 5.5% in the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after buying an additional 331,940 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.